GLP-1 Injection Timing: Day of Week, Time of Day, Fasted or Fed?

Patients ask three timing questions about weekly GLP-1 injections: what day, what time, and does food matter. The pharmacokinetic data settle all three quickly. Semaglutide has an elimination half-life of about 165 hours, roughly 7 days (Lau 2015, J Med Chem^[5]); tirzepatide is about 120 hours, roughly 5 days (Schneck and Urva 2024^[2], Coskun 2018^[6]). Both reach steady state at four to five weeks of weekly dosing. With a half-life that long, the clinically relevant variable is consistency of the weekly interval — not the specific day, time, or meal status. The FDA labels for Wegovy, Ozempic, Mounjaro, and Zepbound say the same thing: pick any day, inject at the same time, and food does not interact with the subcutaneous absorption.

The honest summary

• Any day works. The Wegovy and Ozempic labels explicitly state “the day of weekly administration can be changed if necessary as long as the time between two doses is at least 48 hours (2 days).” The same language appears in the Mounjaro and Zepbound labels. The long half-life makes the specific calendar day irrelevant.
• Any time of day works. Subcutaneous absorption of semaglutide and tirzepatide is not modulated by circadian biology in a clinically meaningful way. There is no published PK study showing a morning-vs-evening difference in efficacy or tolerability for either molecule.
• Fasted vs fed does not matter for injectables. Subcutaneous absorption bypasses gastric emptying entirely. The Hjerpsted 2018 PK work^[1] on semaglutide confirmed gastric emptying is delayed by the drug, not by when the dose is given relative to a meal.
• Pick the day strategically for side effects. Nausea and GI symptoms cluster 24–72 hours after the injection. Injecting Friday evening pushes the worst window into the weekend; injecting Monday gives a recovery window for dose-escalation weeks.
• The exception is oral semaglutide (Rybelsus). Rybelsus requires a 30-minute fast, water only, and no other medications — or absorption falls by more than half. That rule does not apply to injectables.

What the pharmacokinetic data actually show

Semaglutide. Lau 2015^[5] described the molecular design that produces semaglutide’s long half-life: an albumin-binding fatty acid side chain plus substitutions resistant to dipeptidyl peptidase-4 degradation. The published elimination half-life is approximately 165 hours (~7 days), with peak plasma concentration (Tmax) at 1 to 3 days post-dose. Steady state is reached after four to five weekly doses. The Hjerpsted 2018 PK substudy^[1]confirmed that food intake does not modify the subcutaneous absorption profile.

Tirzepatide. Coskun 2018^[6] reported the preclinical and early-clinical PK; Schneck and Urva 2024^[2] published the population PK analysis across healthy volunteers and type 2 diabetes populations. The elimination half-life is approximately 120 hours (~5 days), with Tmax at 24 to 48 hours and steady state at about 4 weeks. The shorter half-life means tirzepatide reaches its weekly trough slightly sooner than semaglutide, but the trough is still well within the therapeutic range.

The practical implication of both half-lives: even if you injected 48 hours early or 48 hours late, plasma concentration would move within the steady-state window. There is no narrow timing requirement. The FDA labels carry a 48-hour minimum between doses, and that is the only hard rule.

Day of the week: strategy, not pharmacology

Because pharmacology is indifferent to the day, the choice is about lifestyle. Two patterns are common and both are defensible.

The “Friday evening” pattern. Gastrointestinal side effects — nausea, mild reflux, early satiety — tend to peak 24 to 72 hours after the weekly dose, with the most severe window in the first 48 hours of dose-escalation weeks. Injecting Friday evening means the worst symptoms fall on Saturday and Sunday, and the recovery window lands before Monday morning. Patients who work Monday to Friday and want symptom-free workdays often prefer this pattern.

The “Monday morning” pattern. Some patients prefer to absorb symptoms during the structured workweek and protect weekends for family events, exercise, or social meals. Monday morning injection delivers the symptom peak Tuesday and Wednesday, with recovery by Friday afternoon.

The constipation lag. Constipation typically develops 3 to 5 days after the dose, not in the first 48 hours. Patients on Wegovy or Zepbound who inject Friday often see constipation peak Monday or Tuesday — the opposite of the nausea timing. Hydration and fiber pacing matter regardless of the day chosen.

Switching the day: keep the 48-hour minimum

The label rule is the same across Wegovy, Ozempic, Mounjaro, and Zepbound: if you need to change the day of the week, the new dose must be at least 48 hours after the prior dose. The long half-life makes the change pharmacologically smooth. For example, moving from Wednesday to Friday is a 48-hour shift forward — allowed. Moving from Wednesday to Tuesday the following week is a 6-day-and-change shift — also fine. The only forbidden interval is < 48 hours from the prior dose.

Once the new day is set, return to a strict weekly schedule. Patients who repeatedly slip the day a few hours forward or backward each week will see slightly wider Cmax variability but no clinical loss of efficacy. The variability that matters is missed doses, not minor day-of-week drift.

Missed dose: the 48-hour rule

The FDA labels for Wegovy, Ozempic, Mounjaro, and Zepbound share the same missed-dose guidance and it is the most important practical rule in this entire article:

• Within 5 days (Mounjaro and Zepbound) or 5 days (Ozempic and Wegovy) of the scheduled day: take the missed dose as soon as you remember. Resume the regular weekly schedule afterward.
• More than 5 days late: skip the missed dose entirely. Take the next dose on the regularly scheduled day. Do not double up.
• Two or more weeks missed: contact your prescriber. A dose reduction during re-titration may be needed to avoid an exaggerated GI side-effect peak when resuming.

Doubling up is the most consequential error: Cmax variability rises sharply, GI symptoms intensify, and the protective slow-titration logic is defeated.

Magnitude: dosing-pattern variability in plasma exposure

Fasted or fed: no, food does not matter for injectables

Subcutaneous injection delivers the drug into the adipose-tissue layer, where it diffuses into capillaries over hours to days. Gastric emptying, meal composition, and food timing have no measurable effect on this absorption pathway. Hjerpsted 2018^[1] measured semaglutide pharmacokinetics in subjects with obesity and found the drug delayed gastric emptying, not the other way around. Tirzepatide PK is similarly food-independent (Schneck and Urva 2024^[2]).

The corollary: the “inject after dinner” folk guidance is harmless but pharmacologically meaningless. Inject when it fits your schedule. The only reason to align with a meal is human routine — pairing the injection with a recurring activity (Sunday morning coffee, Friday evening dinner) reduces missed doses.

The Rybelsus exception

Oral semaglutide (Rybelsus) is the one GLP-1 where food matters profoundly. The Rybelsus label requires:

• Take on an empty stomach, first thing in the morning.
• Use no more than 120 mL (4 oz) of plain water.
• Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications.

Bioavailability of oral semaglutide is only about 0.4 to 1.0% even under optimal fasted conditions; with food in the stomach, bioavailability collapses further. That is why the plasma-variability bar for Rybelsus in our chart above is so much wider than for injectables. For the same dose equivalency, oral patients trade tighter day-of-week flexibility for stricter morning-routine discipline. See our Rybelsus pill vs Ozempic injection comparison for the head-to-head.

Subcutaneous injection technique: 90 degrees, 5–8 mm

The injection technique literature for insulin (Frid 2016^[7]) applies to GLP-1s with one adjustment: GLP-1 pen needles are typically 4 to 6 mm, slightly shorter than legacy insulin needles. The consensus rules:

• Site: abdomen (2 inches from the navel), outer thigh, or back of the upper arm. Rotate weekly to prevent lipohypertrophy. Our injection site rotation calendar gives a printable 12-week schedule.
• Angle: 90 degrees for normal-weight adults with a standard skinfold; 45 degrees only for very lean patients on a 6–8 mm needle, to avoid intramuscular injection.
• Skin pinch: optional with 4–5 mm needles, mandatory with 6–8 mm needles in lean patients. Pinch gently — do not bunch.
• Alcohol prep: let the alcohol dry fully before injecting. Injecting through wet alcohol is the most common cause of sharp stinging.
• Hold time: after pressing the pen button, hold for 6 seconds (Wegovy, Zepbound) or 5 seconds (Ozempic, Mounjaro) before withdrawing.

Pen vs vial

Branded GLP-1s (Wegovy, Ozempic, Mounjaro, Zepbound) ship as prefilled single-use pens or pre-dosed multi-dose pens. Compounded semaglutide and tirzepatide most often ship as multi-dose vials with syringes, because vial-based dosing is substantially cheaper to manufacture.

• Pens are easier and less error-prone; dose is fixed per click; needle is integrated; learning curve is minimal. Cost is higher.
• Vials with syringes require drawing the correct volume (often 0.10–0.50 mL depending on concentration and dose), inverting the vial, expelling air, and verifying the meniscus. The most common error is mis-drawing the dose — either by reading the syringe incorrectly or by using a syringe of the wrong size (a 1 mL syringe read as a 0.5 mL syringe doubles the dose). Ask the dispensing pharmacy to confirm the marked volume and syringe size at the first refill.

Storage and travel

• Refrigerator: 36–46°F (2–8°C). The default storage condition for unopened pens and vials.
• Room temperature: Wegovy and Ozempic pens are stable at up to 86°F (30°C) for up to 28 days after first use. Zepbound and Mounjaro pens are similar. Compounded vials vary by 503A pharmacy — verify the beyond-use date on the label.
• Travel: a soft-sided insulated case with a gel ice pack maintains refrigeration for 24–48 hours. For longer trips, request a TSA-friendly cooler and pack the original pharmacy label.
• Air travel: GLP-1 pens and vials are allowed in carry-on bags with a prescription. Declare them at security if requested. Do not check them — cargo hold temperatures can fall below freezing, which denatures the peptide.

Common timing-related errors

• Doubling up after a missed dose. See the missed-dose section above. If > 5 days late, skip and resume.
• Reusing a pen past 28 days. Even if the pen appears to have medication left, potency declines and bacterial contamination risk rises.
• Drifting the day by 12 hours every week. Over a quarter, the dose creeps from Friday evening to Sunday morning. Clinically minor, but if you keep drifting, formally pick a new day and stay there.
• Injecting into a previously-used site without rotation. Causes lipohypertrophy — lumpy fat deposits that absorb the drug erratically. The single biggest driver of unexplained week-to-week PK variability in long-term users.

Related research and tools

• GLP-1 injection site rotation calendar — printable 12-week schedule preventing lipohypertrophy
• Rybelsus pill vs Ozempic injection — the oral-vs-injectable comparison, fasted-30-minute protocol detail
• GLP-1 side effect duration — when symptoms peak and resolve after each weekly dose
• Oral vs injectable testosterone on GLP-1 — the parallel route-of-administration question for adjunct therapy
• GLP-1 muscle loss prevention protocol — the protein + resistance training pairing that runs alongside the injection schedule

Important disclaimer. This article is educational and does not constitute medical advice. Injection technique, missed-dose handling, and storage instructions should follow the specific FDA label for your prescribed product (Wegovy, Ozempic, Mounjaro, Zepbound) or, for compounded GLP-1s, the beyond-use date and protocol provided by your dispensing 503A pharmacy. Patients with cognitive impairment, visual impairment, or hand-dexterity limitations should request a pen rather than vial format and have injection technique reviewed in person by a prescriber or pharmacist. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if FDA label revisions to Wegovy, Ozempic, Mounjaro, or Zepbound change the missed-dose window or the day-of-week language.